文献速递浆细胞疾病造血干细胞移植与细胞治疗

既往接受异基因移植的多发性骨髓瘤患者的嵌合抗原受体与双特异性T细胞衔接疗法

Chimeric antigen receptor and bispecific T-cell engager therapies in multiple myeloma patients with prior allogeneic transplantation.
PubMed 文献 · Br J Haematol · 2023-12-06

该研究纳入33例既往接受过异基因造血干细胞移植的多发性骨髓瘤患者,其中24例接受CAR-T、9例接受BsAb治疗;CAR-T的ORR为92%(67%≥CR)、73% MRD阴性,BsAb的ORR为44%(44%≥CR)、44% MRD阴性;CAR-T组≥3级不良事件占92%、BsAb组占56%。

要点

  • CAR-T组ORR 92%(67%≥CR)、MRD阴性73%;BsAb组ORR 44%(44%≥CR)、MRD阴性44%。
  • ≥3级不良事件:CAR-T组92% vs BsAb组56%;≥3级感染:CAR-T组50% vs BsAb组44%。
  • 细胞因子释放综合征:CAR-T组83%、BsAb组78%;ICANS仅见于3例CAR-T患者。

核心结论

  • CAR-T与BsAb疗法在既往接受过异基因移植的多发性骨髓瘤患者中似乎可行、安全,并能提供深度且持久的缓解。

研究设计与样本

  • 研究纳入33例既往接受过异基因造血干细胞移植的多发性骨髓瘤患者,其中24例接受CAR-T治疗、9例接受BsAb治疗。

主要发现

  • CAR-T治疗的总缓解率为92%(67%≥完全缓解),73%的患者MRD阴性。
  • BsAb治疗的总缓解率为44%(44%≥完全缓解),44%的患者MRD阴性。
  • 安全性分析显示,CAR-T组92%的患者发生≥3级不良事件,BsAb组为56%。
  • 细胞因子释放综合征在CAR-T组发生率为83%、BsAb组为78%;免疫效应细胞相关神经毒性综合征仅见于3例CAR-T患者。
  • ≥3级感染在CAR-T组报告率为50%、BsAb组为44%;除1例BsAb受者外,未观察到移植物抗宿主病加重。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Chimeric antigen receptor T-cell (CAR-T) therapy and bispecific T-cell engagers (BsAb) have emerged as promising immunotherapeutic modalities in patients with relapsed and/or refractory multiple myeloma (RRMM). However, there is limited data on the safety and efficacy of CAR-T and BsAb therapies in MM patients with a prior history of allogeneic transplantation (allo-HCT). Thirty-three MM patients with prior allo-HCT received CAR-T (n = 24) or BsAb (n = 9) therapy. CAR-T therapy demonstrated an ORR of 92% (67% ≥ CR), and 73% were MRD negative. BsAb therapy resulted in an ORR of 44% (44% ≥ CR) and 44% MRD negative. Safety analysis showed grade ≥3 AEs in 92% of CAR-T and 56% of BsAb patients. Cytokine release syndrome (CRS) occurred in 83% of CAR-T and 78% of BsAb recipients, while immune effector cell-associated neurotoxicity syndrome (ICANS) was observed in three CAR-T patients. Infections of grade ≥3 were reported in 50% of CAR-T and 44% of BsAb recipients. No exacerbation of graft-versus-host disease occurred except in one BsAb recipient. CAR-T and BsAb therapies appear to be feasible, safe and provide deep and durable responses in MM patients with prior allo-HCT.

来源:Br J Haematol,查看原文。版权归原作者所有。

引用

  1. Hammons L, Haider S, Portuguese AJ, et al. Chimeric antigen receptor and bispecific T-cell engager therapies in multiple myeloma patients with prior allogeneic transplantation. Br J Haematol. 2023. PMID: 38054558. doi:10.1111/bjh.19244

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。